drugset / Trial / NCT04935580
Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
Phase 1/2
Unknown
20 enrolled
Shanghai Changzheng Hospital
Gracell Biotechnologies (Shanghai) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, single-center, open-label clinical study to evaluate the safety and efficacy of GC012F in high-risk, transplant eligible patients with NDMM.
Timeline
- Start
- 2021-06-28
- Primary completion
- 2023-07-01
- Completion
- 2023-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC012F | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | GC012F | Cell therapy | 300000 cells/kg | Intravenous |